Pharm Exec’s 20th Annual Pipeline Report examines the emerging drug development trends and surging investments in five ...

Shares of weight loss and diabetes medication maker Novo Nordisk (NYSE: NVO) have slumped precipitously over the past 52 ...

Trump directed a panel headed by HHS Secretary Robert F. Kennedy Jr. to assess “the prevalence of and threat” posed by SSRIs, mood stabilizers, stimulants, and weight-loss drugs.

Pharmaceutical giant Novo Nordisk (NYSE: NVO) released its fourth-quarter and full-year earnings report on Feb. 5. Here are two important insights from that call that should excite investors about ...

You found a weight loss method that works for you: the pounds are coming off, your clothes are fitting better and you’re ...

Independence Blue Cross began limiting coverage of GLP-1 drugs on Jan. 1 to some medical conditions, but not obesity or weight loss.

Novo Nordisk shares dropped due to CagriSema trial results but have long-term upside. Learn why NVO stock is a Strong Buy ...

For years, people taking Ozempic or other drugs in the same class for diabetes and weight loss have noticed the medicines don ...

A new study suggests that using weight loss drugs such as Ozempic and Wegovy can lead to less alcohol consumption. The study, ...

A new study adds to a growing body of research suggesting a potential link between popular GLP-1 medications like Ozempic and ...

Beyond treating diabetes and helping people lose weight, GLP-1s may also improve libido. But the reasons are as complex as ...

From revenue to R&D investment, Novo and Lilly and their mega-blockbuster weight loss drugs Zepbound and Wegovy have moved ...